Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation

MLA

Shiqi Mao, et al. “Outcome Comparison of Pyrotinib with Current Standard of Care in the Second/Third Line Setting in Advanced Non-Small Cell Lung Cancer Patients with HER2 Mutation.” Chinese Medical Journal, vol. 136, Mar. 2023, pp. 848–50. EBSCOhost, https://doi.org/10.1097/cm9.0000000000002453.

APA

Shiqi Mao, Libo Luo, Shuo Yang, Yan Wang, Fei Zhou, Jia Yu, Bin Chen, Guanghui Gao, Xuefei Li, Chao Zhao, Lei Cheng, Yiwei Liu, Wanying Wang, Keyi Jia, Chuchu Shao, Xinyu Liu, Xiaoxia Chen, Chunxia Su, Caicun Zhou, … Shengxiang Ren. (2023). Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation. Chinese Medical Journal, 136, 848–850. https://doi.org/10.1097/cm9.0000000000002453

Chicago

Shiqi Mao, Libo Luo, Shuo Yang, Yan Wang, Fei Zhou, Jia Yu, Bin Chen, et al. 2023. “Outcome Comparison of Pyrotinib with Current Standard of Care in the Second/Third Line Setting in Advanced Non-Small Cell Lung Cancer Patients with HER2 Mutation.” Chinese Medical Journal 136 (March): 848–50. doi:10.1097/cm9.0000000000002453.